ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Steatosis Quantification by MRI PDFF Effectively Identifies Liver Allografts at Low Risk for Recipient Complicationsin Living Donor Liver Transplantation

A. Duarte-Rojo, D. R. Jorgensen, Q. Qi, K. Chupetlovska, A. A. Borhani, A. Furlan, M. Molinari, S. Ganesh, A. Humar

University of Pittsburgh Medical Center, Pittsburgh, PA

Meeting: 2020 American Transplant Congress

Abstract number: D-127

Keywords: Liver transplantation, Living donor, Risk factors

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session D: Liver: Living Donors and Partial Grafts

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Donor TM6SF2 rs58542926 Genotype is a Risk Factor for Liver Graft Steatosis
  • Steatosis by PDFF Affects Percent Remnant Liver Regeneration in Living Donors without Impacting on Clinical Outcomes

*Purpose: Novel methods to assess steatosis, such as proton density fat fraction (PDFF) from MRI provide an accurate and continuous quantification of mild steatosis. We hypothesized that assessment of steatosis with PDFF could identify and risk-stratify live donors without the need for a liver biopsy.

*Methods: Mild steatosis was defined as a PDFF 6.4-17.4%, moderate 17.4-22.1%, and severe>22.1%. PDFF was obtained as standard of care in all of our live donors evaluated between June 2018 and September 2019 at University of Pittsburgh Medical Center. In the recipients, we collected laboratories during the first posttransplant week along with clinical outcomes including standard definitions for primary non-function (PNF), early allograft dysfunction (EAD), and small for size syndrome (SFSS).

*Results: Out of 86 potential donors, 60 (70%) had no steatosis and 27 (30%) had steatosis (mild in 23 [85%], moderate and severe in 2 [7%] each). Forty-six (53%) proceeded with donation, all with mild steatosis (maximum PDFF 16.4%). The average PDFF for donors with steatosis was 9.9±2.5% and 2.9±1.3% in its absence (p<0.001), with no distinct features between donors with or without steatotic livers (age 42±9 vs. 37±10; White 91 vs. 97; BMI 28±3 vs. 26±4). Recipients of a steatotic liver were slightly older 64±7 than those without steatosis (57±13; p=0.02), however, there were no differences when considering biologically related donation (46% vs. 39%; p=0.7), graft weight to recipient weight ratio (1.1±0.4 vs. 1.1±0.2; p=0.9) or MELD (15±8 vs. 16±6; p=0.7). We found no significant differences in post-transplant labs and length of hospital stay (8 [7-11] vs. 10 [7-15] days) between recipients receiving a graft with or without steatosis (all p’s>0.05), and no cases of EAD, PNF or SFSS were identified. There were 3 graft losses / recipient deaths, 2 in the group without steatosis and 1 in the group with steatosis, related to hepatic artery thrombosis, multiorgan failure, and mesenteric ischemia.

*Conclusions: Noninvasive assessment of steatosis with PDFF allowed the identification of live donor allografts suitable for transplantation. Although transplant outcomes using allografts with a PDFF above 16.4% cannot be known, our findings support the use of PDFF to predict successful transplantation when donors with no or mild steatosis are considered.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Duarte-Rojo A, Jorgensen DR, Qi Q, Chupetlovska K, Borhani AA, Furlan A, Molinari M, Ganesh S, Humar A. Steatosis Quantification by MRI PDFF Effectively Identifies Liver Allografts at Low Risk for Recipient Complicationsin Living Donor Liver Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/steatosis-quantification-by-mri-pdff-effectively-identifies-liver-allografts-at-low-risk-for-recipient-complicationsin-living-donor-liver-transplantation/. Accessed March 4, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.